Skip to content

Reprogramming is the

next leap forward in cancer immunotherapy

ABOUT ASGARD THERAPEUTICS

CEO Cristiana Pires speaks at BIO-Europe about Asgard Therapeutics and explains how TrojanDC works.

Asgard Therapeutics has the ambitious goal to establish direct cell reprogramming as an entirely new approach to unleash the immune system against cancer.

Learn more

Asgard is developing TrojanDC, the world’s first cancer immunotherapy based on dendritic cell reprogramming, forcing cancer cells to become immunogenic again.

OUR TEAM

Asgard was created by some of the brightest researchers in the cell reprogramming field. In the end, we hope our work will make a measurable impact in patients’ life. Meet our team